Head-to-head · Cost-Efficiency Index
HealthRX vs Maves
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
HealthRX
Shoppers who want the whole term ladder published before intake and are reading it carefully enough to spot which rung the headline came from.
Visit HealthRXMaves
Shoppers drawn to aggressive low intro pricing on semaglutide who will confirm the exact charge before checkout.
Visit MavesThe verdict
Maves takes it, leading the Cost-Efficiency Index 76 to 74. Maves (operated by parent company Homera Health) is a men's-health/performance-framed telehealth platform offering compounded semaglutide and tirzepatide plus sermorelin. HealthRX still earns a C — Shoppers who want the whole term ladder published before intake and are reading it carefully enough to spot which rung the headline came from.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Maves.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | HealthRX | Maves |
|---|---|---|
| Cost-Efficiency Index | 74/100 | 76/100 |
| Semaglutide / mo | $190/mo (all doses, compounded) | $89/mo (starting dose, compounded) |
| Tirzepatide / mo | $239/mo (all doses, compounded) | Not disclosed |
| Semaglutide / yr (modeled) | $2,280 | $1,068 |
| Tirzepatide / yr (modeled) | $2,868 | — |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #46 | #49 |
HealthRX
74/100Where the value is
- All 50 states, printed in the site's own header strip rather than left to the intake quiz
- Specific, checkable LegitScript certificate number (50087439) rather than just a generic badge image
- "Same price at every dose" policy avoids dose-based price creep
The tradeoffs
- The advertised $99 and $179 are twelve-month prepay rungs — $1,188 and $2,148 up front. The standing month-to-month rates are $190 and $239, roughly double and a third higher
- A second discount is stacked on the same headline: $99 semaglutide and $149 tirzepatide are also first-month intro rates on the monthly plan, so month two costs more than month one
Maves
76/100Where the value is
- LegitScript badge displayed on the site
- Publishes the FDA compounded-medication disclaimer
- Low advertised semaglutide entry price ($89-99/mo range)
The tradeoffs
- The homepage shows two different numbers for the same starting semaglutide tier ($89/month vs $99 first month) with no reconciliation — the real ongoing price cannot be confirmed from the public site
- Tirzepatide is listed as an offering but no price is published anywhere reachable on the site, confirmed by direct search
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.